

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

**保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1246)**

### **(1) FURTHER DELAY IN PUBLICATION OF THE 2022 AUDITED ANNUAL RESULTS AND DESPATCH OF THE 2022 ANNUAL REPORT; AND (2) POSTPONEMENT OF BOARD MEETING**

References are made to the announcements (the “**Announcements**”) of Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 June 2022 and 19 July 2022 in relation to, among other things, (i) the unaudited annual results of the Group for the year ended 31 March 2022; (ii) delay in publication of the audited annual results of the Group for the year ended 31 March 2022 (the “**2022 Audited Annual Results**”); (iii) the date of the meeting of the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company originally scheduled to be held on 29 July 2022, for the purpose of, among others, considering and approving the 2022 Audited Annual Results; and (iv) delay in despatch of annual report of the Company for the year ended 31 March 2022 (the “**2022 Annual Report**”).

#### **FURTHER DELAY IN PUBLICATION OF THE 2022 AUDITED ANNUAL RESULTS AND DESPATCH OF THE 2022 ANNUAL REPORT**

Due to the impact of the outbreak of COVID-19 pandemic, the audit procedures of the Group could not be completed as scheduled and the Company previously announced that (i) the 2022 Audited Annual Results was expected to be published on or before 29 July 2022; and (ii) the 2022 Annual Report was expected to be published on or before 4 August 2022 and despatched to the shareholders of the Company (the “**Shareholders**”) by 5 August 2022.

The Board wishes to update the Shareholders and potential investors that, as at the date of this announcement, the audit procedures of the Group could not be completed as scheduled, and such delay was mainly attributable to (i) the further delay in obtaining confirmations from certain banks and a financial institution as a result of the quarantine and logistics restrictions in parts of the Mainland China to combat the COVID-19 pandemic; and (ii) the delay in audit procedures which

require assessment on the Group's ability to continue as a going concern. As a result, the Company is unable to publish the 2022 Audited Annual Results by 29 July 2022, and will be unable to despatch the 2022 Annual Report by 5 August 2022 as previously intended.

Based on the information currently available to the Company and the current progress of the audit process, it is expected that the 2022 Audited Annual Results as agreed with the auditors of the Company (the "Auditors") will be published on or about 8 August 2022, and the 2022 Annual Report will be published on the websites of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Company on or about 12 August 2022 and despatched to the Shareholders by 15 August 2022.

The Board wishes to supplement that the Company has been using its best endeavours to assist the Auditors in completing the audit work. As at the date of this announcement, based on the information available to the Company, save for uncertainties relating to going concern as mentioned above, the Company is not aware of any key audit issue identified or any inside information relating to the 2022 Audited Annual Results which needs to be brought to the attention of the Shareholders and the Stock Exchange.

#### **POSTPONEMENT OF BOARD MEETING**

In light of the further delay in finalising the 2022 Audited Annual Results, the Board meeting originally scheduled to be held on 29 July 2022 for the purpose of, among others, considering and approving the 2022 Audited Annual Results and its publication, and considering the payment of a final dividend, if any, will be postponed.

Further announcement(s) will be made by the Company as and when appropriate to inform the Shareholders of the date of the Board meeting and any material developments in the matter above.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 29 July 2022

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*